Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis

被引：38

作者：

Selvaggio, Anna S. ^{[1
]}

Noble, Paul W. ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA

来源：

ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷

关键词：

pirfenidone; idiopathic pulmonary fibrosis; interstitial lung disease; Esbriet (R); NECROSIS-FACTOR-ALPHA; OPEN-LABEL; PHASE-3; TRIAL; DOUBLE-BLIND; SURVIVAL; ACETYLCYSTEINE; PROLIFERATION; ACTIVATION; CAPACITY; RECEPTOR;

D O I：

10.1146/annurev-med-120214-013614

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of survival. Recently, great strides have been made in the development of pharmaceutical therapy to treat IPF. Pirfenidone, an oral antifibrotic agent, has been shown to slow progression of the disease and improve progression-free survival, offering new hope for patients suffering from IPF.

引用

下载

页码：487 / 495

页数：9

共 50 条

[21] Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Bonella, F.
Wessendorf, T. E.
Costabel, U.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (11) : 518 - 523
[22] Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis
Loeh, Benjamin
Drakopanagiotakis, Fotios
Bandelli, Gian Piero
von der Beck, Daniel
Tello, Silke
Cordani, Elisa
Rizza, Elvira
Barrocu, Laura
Markart, Philipp
Seeger, Werner
Guenther, Andreas
Albera, Carlo
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (01) : 110 - 113
[23] A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis
Anderson, Adam
Shifren, Adrian
Nathan, Steven D.
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 975 - 982
[24] Pirfenidone: A Novel Agent for the Treatment of Idiopathic Pulmonary Fibrosis
Potts, Jason
Yogaratnam, Dinesh
ANNALS OF PHARMACOTHERAPY, 2013, 47 (03) : 361 - 367
[25] Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis
Hilberg, Ole
Simonsen, Ulf
du Bois, Roland
Bendstrup, Elisabeth
CLINICAL RESPIRATORY JOURNAL, 2012, 6 (03): : 131 - 143
[26] New era of Idiopathic Pulmonary Fibrosis
Kishaba, Tomoo
RESPIRATORY INVESTIGATION, 2018, 56 (06) : 427 - 429
[27] Pirfenidone in idiopathic pulmonary fibrosis: Is there a role?
Galal, I.
EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2014, 63 (04): : 749 - 750
[28] Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Flaherty, Kevin R.
Fell, Charlene D.
Huggins, J. Terrill
Nunes, Hilario
Sussman, Robert
Valenzuela, Claudia
Petzinger, Ute
Stauffer, John L.
Gilberg, Frank
Bengus, Monica
Wijsenbeek, Marlies
EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
[29] Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
Aimo, Alberto
Spitaleri, Giosafat
Nieri, Dario
Tavanti, Laura Maria
Meschi, Claudia
Panichella, Giorgia
Lupon, Josep
Pistelli, Francesco
Carrozzi, Laura
Bayes-Genis, Antoni
Emdin, Michele
CARDIAC FAILURE REVIEW, 2022, 8
[30] Pirfenidone and mortality in idiopathic pulmonary fibrosis
Spagnolo, Paolo
LANCET RESPIRATORY MEDICINE, 2017, 5 (01): : 3 - 5

← 1 2 3 4 5 →